Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q13438

UPID:
OS9_HUMAN

ALTERNATIVE NAMES:
Amplified in osteosarcoma 9

ALTERNATIVE UPACC:
Q13438; A6NDD1; A6NFR7; A6NLB2; A8K5Q9; B4DE28; B4DPX1; B4E1I6; E7ENT8; E7EW91; F8VUH2; G3XA88; O00579; Q6IBL2; Q8IZ58; Q9BW99

BACKGROUND:
The Protein OS-9, identified by the alternative name Amplified in osteosarcoma 9, is integral to the protein quality control system within the endoplasmic reticulum (ER). It specializes in identifying both non-glycosylated and improperly folded glycoproteins, retaining them within the ER to prevent further misfolding and potentially facilitating their degradation. This process is crucial for maintaining cellular health and function, with TRPV4 being a notable target of OS-9.

THERAPEUTIC SIGNIFICANCE:
The exploration of Protein OS-9's function offers a promising avenue for therapeutic intervention. Its critical role in managing protein misfolding and degradation within the ER underscores its potential in developing treatments for related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.